Viral & Non-Viral Vector Manufacturing Market to Grow with a CAGR of 20.72% through 2030
Rising prevalence of fatal
diseases to drive the viral & non-viral vector manufacturing market in the
forecast period, 2026-2030.
According to TechSci Research report, “Viral
& Non-Viral Vector Manufacturing Market - Global Industry
Size, Share, Trends, Opportunity, and Forecast, 2030”, the Global Viral & Non-Viral Vector Manufacturing Market was valued at USD 8.21 billion in 2024 and is expected to reach USD 25.41 billion by 2030 with a CAGR of 20.72% during the forecast period. The growing prominence of gene and cell therapy products and
rising incidences of genetic disorders, cancers, and infectious diseases are
the primary factors driving the demand for the global viral & non-viral
vector manufacturing market. Growing technological advancements, increasing
number of clinical studies, and rising funding activities driving research
related to vector-based therapies are expected to influence the market demand. Also,
the robust pipeline of gene and cell therapy products along with vector-based
vaccines, are increasing the growth of the market, globally.
However, the high cost of vector manufacturing,
low transfection efficiency, and complications associated with large-scale
production of viral and non-viral vectors may likely hamper the growth of the
global viral & non-viral vector manufacturing market.
Browse over XX market
data Figures spread through XX Pages and an in-depth TOC on "Global Viral & Non-Viral Vector Manufacturing Market"
The global viral &
non-viral vector manufacturing market is segmented into vector type,
indication, application, regional distribution and company.
Based on Indication, the cancer segment is showing the fastest growth, driven by the rapid expansion of oncology-focused gene therapies, immunotherapies, and cell-based treatments such as CAR-T therapies. Cancer remains one of the most significant global health challenges, and governments, research institutions, and pharmaceutical companies are investing heavily in advanced therapies that rely on vector-based platforms. According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide, accounting for nearly 10 million deaths in 2022. In the United States, the National Cancer Institute (NCI) estimated over 2 million new cancer cases in 2024, reflecting the growing disease burden. This high prevalence has created strong demand for innovative therapies beyond traditional chemotherapy and radiation, with viral and non-viral vectors at the core of next-generation oncology solutions. A major growth driver is the development and approval of CAR-T cell therapies, which use viral vectors (mainly lentiviruses and retroviruses) for genetic modification of patient T-cells. The U.S. FDA has already approved multiple CAR-T therapies for blood cancers, and dozens more are in clinical trials for solid tumors. The NIH’s Cancer Moonshot Program, which received a renewed federal budget of USD 1.8 billion between 2023–2027, prioritizes novel immunotherapies and vector-based cancer treatments, further fueling growth in this segment.
Based on the Region, the Asia Pacific region is projected to record the fastest growth in the global viral and non-viral vector manufacturing market, driven by expanding healthcare infrastructure, rising prevalence of genetic and chronic diseases, and significant government investments in biotechnology and advanced therapeutics. Countries such as China, India, Japan, and South Korea are at the forefront of this growth due to their strong focus on biopharmaceutical manufacturing and clinical research. China has emerged as a major hub for gene and cell therapy development. According to the China National Medical Products Administration (NMPA), the country had over 1,400 registered clinical trials in cell and gene therapy by 2023, placing it second only to the United States. The Chinese government’s 14th Five-Year Plan emphasizes biotechnology innovation, with targeted funding for gene therapy, regenerative medicine, and vaccine development, all of which require viral and non-viral vectors. Similarly, India’s Department of Biotechnology (DBT) has launched programs to promote indigenous biomanufacturing and gene therapy research, including plasmid DNA-based vaccine development, which boosts non-viral vector demand.
Major companies operating
in Global Viral & Non-viral Vector Manufacturing market are:
- Catalent, Inc.
- FUJIFILM Holdings Corporation
- Danaher Corporation
- Genscript Biotech Corporation
- Lonza Group AG
- Merck KGaA Inc.
- Oxford Biomedica plc
- Sartorius AG
- Takara Bio Inc.
- Thermo Fisher Scientific Inc.
Download Free Sample Report
Customers can also
request for 10% free customization on this report.
“North America region dominates the market and is expected to maintain
its dominance in the coming years due to its sophisticated healthcare services
and elevated cancer prevalence rate. The increasing number of company collaborations, heavy investments in R&D, growing urbanization, presence of a
significant number of research centers, and advancement in technology are propelling
the market growth. Also, increasing R&D activities in vector-based therapy
innovations in the region are expected to propel the global viral &
non-viral vector manufacturing market growth” said Mr. Karan Chechi,
Research Director of TechSci Research, a research based global management
consulting firm.
“Viral & Non-Viral
Vector Manufacturing Market - Global Industry Size, Share, Trends, Opportunity,
and Forecast, Segmented By Vector Type (Viral Vector v/s Non-Viral
Vector), By Indication (Cancer, Genetic Disease, Infectious Disease,
Cardiovascular Diseases, Others), By Application (Gene Therapy, Vaccinology,
Cell Therapy, Others), By Region and Competition, 2020-2030F”, has evaluated the future growth
potential of global viral & non-viral vector manufacturing market and
provides statistics & information on market size, structure, and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in global viral & non-viral vector
manufacturing market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com